ID: ALA3623790

Max Phase: Preclinical

Molecular Formula: C69H104N20O17S2

Molecular Weight: 1549.85

Molecule Type: Protein

Representations

Canonical SMILES:  CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]3CCCN3C(=O)[C@@H]3CCCN3C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N2

Standard InChI:  InChI=1S/C69H104N20O17S2/c1-7-34(4)53-64(102)78-40(18-12-22-74-69(72)73)57(95)81-44(31-90)59(97)86-55(36(6)9-3)68(106)89-25-15-21-49(89)67(105)88-24-14-20-48(88)63(101)85-54(35(5)8-2)65(103)83-45-32-107-108-33-46(61(99)84-53)82-58(96)41(26-37-29-75-39-17-11-10-16-38(37)39)77-52(93)30-76-56(94)42(27-50(70)91)79-62(100)47-19-13-23-87(47)66(104)43(28-51(71)92)80-60(45)98/h10-11,16-17,29,34-36,40-49,53-55,75,90H,7-9,12-15,18-28,30-33H2,1-6H3,(H2,70,91)(H2,71,92)(H,76,94)(H,77,93)(H,78,102)(H,79,100)(H,80,98)(H,81,95)(H,82,96)(H,83,103)(H,84,99)(H,85,101)(H,86,97)(H4,72,73,74)/t34-,35-,36-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,53-,54-,55-/m0/s1

Standard InChI Key:  VRMZLUPLYRHORK-GIBJNIQWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Protein

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 1549.85

Molecular Weight (Monoisotopic): 1548.7330

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. de Veer SJ, Wang CK, Harris JM, Craik DJ, Swedberg JE..  (2015)  Improving the Selectivity of Engineered Protease Inhibitors: Optimizing the P2 Prime Residue Using a Versatile Cyclic Peptide Library.,  58  (20): [PMID:26393374] [10.1021/acs.jmedchem.5b01148]

Source

Source(1):

• Scientific Literature